2017

150.00 rub.
Buy article
2017/№7

Adherence to Therapy in the Outpatient Setting: the Ability to Identify and Assess the Effectiveness of Therapy

Fofanova T. V.1, Ageev F. T.1, Smirnova M. D.1, Deev A. D.2
1Institute of Cardiology of Russian Cardiology Scientific and Production Complex, Moscow, Russia
2State Institution National Research Center for Preventive Medicine, Moscow, Russia

Keywords: arterial hypertension; adherence to treatment; treatment in outpatient setting

DOI: 10.18087/cardio.2017.7.10004

Aim. To assess adherence of patients to antihypertensive therapy, to determine the role of various factors affecting adherence to treatment by outpatients, and to assess clinical efficacy of a calcium antagonist felodipine. Material and methods. We examined 5 474 women and men aged >18 years who at visit to a local internist had office systolic arterial pressure (AP) 140–179 and diastolic AP up to 100 mm Hg both on and without hypotensive therapy. Examination included registration of risk factors and concomitant therapy. All patients self-assessed their state of heath using visual analog scale (VAS). Adherence to therapy was evaluated by the Morisky-Green test. Obtaining by a patient of antihypertensive drugs in the framework of the Programme for Supplementary Pharmaceutical Provision (SPP) was necessarily registered. Results. Among examined ambulatory patients with arterial hypertension (AH) and ischemic heart disease (IHD) more than 60% had low adherence to prescribed medications. Such factors as complicated AH course when AH was combined with IHD or diabetes (D), use of angiotensin converting enzyme inhibitors, calcium antagonists, and angiotensin receptor blockers were associated with high adherence to treatment. Male sex, elderly age, presence of risk factors of cardiovascular complications, and long history of AH were associated with low adherence to therapy. Presence of prescribed drugs in the SSP list was associated with high adherence but multifactorial analysis with inclusion of IHD, D, availability of a tonometer at home made contribution of SSP in high adherence insignificant. The use of felodipine allowed not only to achieve pronounced hypotensive effect in patients with AH but also to improve initially low adherence. Conclusion. During long-term observation of outpatients, it is necessary to regularly assess possibly low adherence to therapy with the aim of its improvement.
  1. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34:2159–2219.
  2. Oganov R. G., Maslennikova G. Ya. Demographic trends in the Russian Federation: the impact of cardiovascular disease. Cardiovascular Therapy and Prevention 2012;11 (1):5–10. Russian (Оганов Р. Г., Масленникова Г. Я. Демографические тенденции в Российской Федерации: вклад болезней системы кровообращения. Кардиоваскулярная терапия и профилактика 2012;1:5–10).
  3. Shalnova S. A., Konradi A. O., Karpov Yu. A. et al. Cardiovascular mortality in 12 Russian Federation regions – participants of the “Cardiovascular Disease Epidemiology in Russian Regions” study. Russ J Cardiol 2012;5 (97):6–11. Russian (Шальнова С. А., Конради А. О., Карпов Ю. А. и др. Анализ смертности от сердечно-сосудистых заболеваний в 12 регионах Российской Федерации, участвующих в исследовании «Эпидемиология сердечно-сосудистых заболеваний в различных регионах России». Российский кардиологический журнал 2012;5 (97):6–11).
  4. Diagnosis and treatment of hypertension. Recommendations of the Russian Medical Society for Arterial Hypertension (RIOH) and the All-Russian Scientific Society of Cardiologists (VNOK) (fourth revision). Systemic hypertension 2010;3:5–26. Russian (Диагностика и лечение артериальной гипертензии. Рекомендации Российского медицинского общества по артериальной гипертонии (РМОАГ) и Всероссийского научного общества кардиологов (ВНОК) (четвертый пересмотр). Системные гипертензии 2010;3:5–26).
  5. Cooper De Hoff R.M., Handberg E.M., Mancia G. et al. INVEST revisited: review of findings from International Verapamil SR-Trandolapril Study. Expert Rev Cardiovasc Ther 2009;7:1329–1340.
  6. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. JAMA 2002;288:2981–2997.
  7. Pepine C.J., Handberg E.M., Cooper-De Hoff R.M. et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International verapamil-trandolapril study (INVEST): a randomized controlled trial. JAMA 2003; 290:2805–2816.
  8. Claxton A.J., Cramer J., Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2012; 23:1296–1310.
  9. Simpson S.H., Eurich D.T., Majumdar S.R. et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006; 333:15–20.
  10. Sokol M.G., McGuigan K. A., Verbrugge R . et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005; 43 (6):521–530.
  11. Krousel-Wood M., Thomas S., Munter P. et al. Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol 2004;19 (4):357–362.
  12. Mancia G., Zambon A., Soranna D. et al. Factors involved in the discontinuation of antihypertensive drug therapy: an analysis from real life data. J Hypertens 2014;32 (8):1708–1715.
  13. Mazzaglia G., Ambrosioni E., Alacqua M. et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation 2009;120 (16):1598–1605.
  14. Leonova M. V., Shteinberg L. L., Belousov Yu. V. еt al. Pharmacoepidemiology of arterial hypertension in Russia: an analysis of the adherence of physicians (according to the results of the study PIFAGOR IV). Systemic hypertension 2015,1:19–25. Russian (Леонова М. В., Штейнберг Л. Л., Белоусов Ю. В. и др. Фармакоэпидемиология артериальной гипертонии в Россиии: анализ приверженности врачей (по результатам исследования ПИФАГОР IV). Системные гипертензии 2015;1:19–25)
  15. Bosworth H.B., Granger B.B., Mendys P. et al. Medication Adherence: A Call for Action. Am Heart J 2011;162 (3):412–424.
  16. 2007 Guidelines for the management of arterial hypertension. Eur Heart J 2007;28:1462–1536.
  17. Morisky D.E., Green L.W., Levine D.M. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986;24:67–74.
  18. O’Riordan M. Cost-Sharing Prescription Drug Initiatives Further Reduce Adherence to Statin Therapy. Heartwire from Medscape. http://www.medscape.com/viewarticle/554885 (09April 2007).
  19. Recommendations for the treatment of arterial hypertension. ESH/ESC2013. Working group on the treatment of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (European Society of Cardiology, ESC). Russian Cardiology Journal 2014;1:7–94. Russian (Рекомендации по лечению артериальной гипертонии. ESH/ESC2013. Рабочая группа по лечению артериальной гипертонии Европейского Общества Гипертонии (European Society of Hypertension, ESH) и Европейского Общества Кардиологов (European Society of Cardiology, ESC). Российский кардиологический журнал 2014;1:7–94).
  20. Naderi S.H., Bestwick J.P., Wald D.S. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med 2012;125 (9):882–887.
  21. Fodor G.J., Kotrec M., Bacskai K. et al. Is interview a reliable method to verify the compliance with antihypertensive therapy? An international Central-European study. J Hypertens 2005;23:1261–1266.
  22. Baggarly S.A., Kemp R.J., Wang X. et al. Factors associated with medication adherence and persistence of treatment for hypertension in a Medicaid population. Res Social Adm Pharm 2014;10 (6):e99–112.
  23. Barreto M.D., Cremonese I.Z., Janeiro V. et al. Prevalence of non-adherence to antihypertensive pharmacotherapy and associated factors. Rev Bras Enferm 2015;68 (1):60–67.
  24. Conn V.S., Hafdahl A.R., Cooper P.S. et al. Interventions to Improve Medication Adherence Among Older Adults: Meta-Analysis of Adherence Outcomes Among Randomized Controlled Trials. Gerontologist 2009; 49 (4):447–462.
  25. Lo S.H., Chau J.P., Woo J. et al. Adherence to antihypertensive medication in older adults with hypertension. J Cardiovasc Nurs 2016; 31 (4):296–303.
  26. Rao C.R., Veena K.G., Shetty A. et al. Treatment Compliance among patients with hypertension and type 2 diabetes mellitus in a coastal population of Southern India. Int J Prev Med 2014;5 (8):992–998.
  27. Reach G., Guedj-Meynier D., Darné B. et al. Factors associated with medication non-adherence in uncontrolled hypertensive males and females:ODACE study. Ann Cardiol Angeiol (Paris). 2015;64 (3):222–226.
  28. Couto J.E., Panchal J.M., Lal L.S. et al. Geographic variation in Medication Adherence in Commercial and Medicare Part D Populations. J Manag Care Pharm 2014;20 (8):834–842.
  29. Kulkarni S.P., Alexander K.P., Heiss G. et al. Long-term adherence with cardiovascular drug regimens. Am Heart J 2006;151 (1):185–191.
  30. Munger M.A., Van Tassell B.W., LaFleur J. Medication nonadherence: an unrecognized cardiovascular risk factor. Med Gen Med 2007;9 (3):58–60.
  31. Beune E.J., Moll van Charante E.P., Beem L. et al. Culturally adapted hypertension education (CAHE) to improve blood pressure control and treatment adherence in patients of African origin with uncontrolled hypertension: cluster-randomized trial. PLoS One 2014;9 (3):1–11.
  32. Cooper L.A., Roter D.L., Carson K.A. et al. A randomized trial to improve patient-centered care and hypertension control in underserved primary care patients. J Gen Intern Med 2011;26 (11):1297–1304.
  33. Quan H., Chen G. Antihypertensive medication adherence and mortality according to ethnicity: a cohort study. Can J Cardiol 2014;30 (8):925–931.
  34. Nwabuo C.C., Dy S.M., Weeks K. et al. Factors Associated with Appointment Non-Adherence among African-Americans with Severe, Poorly Controlled Hypertension. PLOS ONE 2014;9 (8):1–7.
  35. Seo I., Seong S.I., Suh M-H. et al. Genome-Wide Association Study of Medication Adherence in Chronic Diseases in the Korean Population. Genomics Inform 2014;12 (3):121–126.
  36. Wang W., Lau Y., Loo A. et al. Medication adherence and its associated factors among Chinese community-dwelling older adults with hypertension. Heart Lung 2014;43 (4):278–283.
  37. Zanchetti A., Hansson L., Clement D. et al. Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles: does a J-shaped curve exist in smokers? J Hypertens 2003;21:797–804.
  38. Jonsson B., Hansson L., Stalhammar N.O. Health economics in the Hypertension Optimal Treatment (HOT) study: costs and cost – effectiveness of intensive blood pressure lowering and low – dose aspirin in patients with hypertension. J Intern Med 2003;253:472–480.
  39. Hansson L., Lindholm L.H., Ekbom T. et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension – 2 study. Lancet 1999;354:1751–17564.
  40. Liu L., Zhang Y., Liu G. et al. The Felodipine EVEnt Reduction (FEVER) study: A randomized long – term placebo controlled trial in Chinese hypertensive patients. J Hypertens 2005;12:2157–2172.
  41. Zhang Y., Zhang X., Liu L. et al. Effects of individual risk factors on the residual risk of cardiovascular events in a population of treated Chinese patients with hypertension: data from the Felodipine Event Reduction (FEVER) study. J Hypertens 2010;28 (10):2016–2025.
  42. Corrao G., Soranna D., La Vecchia C. et al. Medication persistence and the use of generic and brand-name blood pressure-lowering agents. J Hypertens 2014;32 (5):1146–1153.
  43. Haynes R.B., McKibbon K. A., Kanani R . Systematic review of randomized trials of interventions to assists patients to follow prescriptions for medications. Lancet 1996;348:383–386.
  44. Campbell D.J. T., Ronksley P.E., Manns B.J. et al. The Association of Income with Health Behavior Change and Disease Monitoring among Patients with Chronic Disease. PLoS One 2014;9 (4): e94007.
  45. Ye X., Gross C.R., Schommer J., et al. Association between copayment and adherence to statin treatment after coronary heart disease hospitalization; a longitudinal, retrospective, cohort study. Clin Ther 2007;29 (12):2748–2757.
Fofanova T. V., Ageev F. T., Smirnova M. D., Deev A. D. Adherence to Therapy in the Outpatient Setting: the Ability to Identify and Assess the Effectiveness of Therapy. Kardiologiia. 2017;57(7):35–42.

To access this material please log in or register

Register Authorize
Ru En